Breaking AI & Tech News Analyzed

Goldman Sachs's chief executive, David Solomon, has expressed heightened awareness of the capabilities of Anthropic's Mythos AI model and is collaborating closely with the tech firm following warnings about the cybersecurity risk it poses.The US bank has been closely monitoring the rapid advancements in artificial intelligence, including large language models (LLMs), as part of broader efforts to protect itself from hackers.“Obviously the LLMs are making rapid progress and we’re hyper-aware of the enhanced capabilities of these new models with the help of the US government and the model publishers,” Solomon told analysts on an earnings call on Monday.Anthropic, the company behind the Claude family of AI tools, claimed last week that its latest model, Mythos, posed an unprecedented risk due to its ability to expose flaws in IT systems. The company warned that AI models have reached a level of coding capability where they can surpass all but the most skilled humans at finding and exploiting software vulnerabilities.Solomon emphasized that Goldman Sachs is working closely with Anthropic and all of its security vendors to harness frontier capabilities. “We are very focused on supplementing our cyber and infrastructure resilience. And this is part of our ongoing capabilities that we have been investing in, and are accelerating our investment in.”The news comes after the US Treasury secretary, Scott Bessent, summoned Solomon and other big American bankers to Washington to discuss the Mythos model last week. The meeting focused on heads of so-called systemically important banks, where regulators believe that a major disruption to their operations, or their potential collapse, would put financial stability at risk.On Monday, the UK government’s AI Security Institute (AISI) warned that Mythos was a “step up” over previous models in terms of the cyber threat it posed. AISI said Mythos could carry out attacks that required multiple actions and discover weaknesses in IT systems without human intervention.

A 10-metre long humpback whale that became stranded on a sandbar in the Baltic Sea last month has left experts and the German public in a state of distress. The male whale, which has repeatedly stranded and freed itself, is now stranded once more and in the throes of death.The drama has captivated the country, drawing politicians, shamans, and animal rights activists to the scene. Experts have faced death threats and accusations of worsening the whale's plight, with some calling for the far right to take power.The local mayor has admitted: 'We have all been totally out of our depth.' A leading humpback whale expert has even stopped allowing her name to be quoted in the media, citing the danger of talking about humpback whales in Germany.The whale's condition has rapidly declined due to a fishing net caught in its jaw, weakening it and leading to a loss of direction. The Baltic Sea's low salt levels and shallow waters are not suitable for the whale's survival. Wounds and infections have been detected on its body, with experts describing it as 'very sick.'Despite the emotional public outcry and various rescue suggestions, including using cranes, planes, and inflatable pontoons, authorities have declared the whale beyond saving. The environment minister of Mecklenburg-Vorpommern, Till Backhaus, has pleaded with the public to leave the animal in peace to die, saying it has been one of the most demanding operations of his 27 years in office.

Monarch Collective believes that a number of Women’s Super League (WSL) clubs remain “afterthoughts” for their owners, receiving only marginal capital and expertise. Co‑founder Kara Nortman highlighted this concern during a recent interview.Last month, Monarch became the first women’s multi‑sport group by acquiring a minority stake in the Cleveland WNBA franchise, joining an ownership portfolio that already includes NWSL sides San Diego Wave and Boston Legacy, as well as German club Viktoria Berlin.Since establishing Monarch in 2023—four years after launching Angel City FC with Natalie Portman and Julie Uhrman—Nortman has held informal talks with roughly a dozen English clubs, though no deal has yet materialised. She declined to comment on ongoing negotiations with West Ham United’s women’s side, noting that finding the right English partner has proven “challenging”.Recent years have seen a wave of international interest in WSL clubs, yet many prospective investors perceive the women’s teams as a compliance tool for profitability and sustainability mandates rather than a growth engine. In the past twelve months, clubs such as Chelsea, Aston Villa and Everton have sold stakes in their women’s sides to related‑party entities, while US‑based Bay Collective recently secured majority ownership of Sunderland Women in the WSL2.Monarch’s latest $250 million funding round equips it with the capital to act when a suitable opportunity arises. Nortman explained, “If owners truly believe in their women’s team, they should invite us to ‘supercharge’ it with our cross‑sport expertise. If they only want a token boost, that’s a different story.”Beyond capital, Monarch offers advisory services. Nortman recounted a humorous encounter with fans at Crystal Palace, where a supporter asked if she was a “Wag”, prompting a light‑hearted response that underscored the firm’s community‑focused ethos.Reflecting on Angel City’s trajectory, Nortman noted that Monarch initially invested about $1 million to help the club join the NWSL in 2020. Four years later, Angel City was sold to Disney CEO Bob Iger and his wife for a reported $250 million, making it the world’s most valuable women’s franchise.Looking ahead, Monarch is broadening its scope beyond football and basketball, exploring opportunities in cricket and rugby union. The firm recently opened a London office, led by former Manchester City executive Katharine Curran, to deepen its engagement with the UK sports market.

The Olivier Awards, a prestigious event in the theatre world, recently took place, and among the many memorable moments were the quotes shared by the winners. Host Nick Mohammed kicked off the ceremony with a lighthearted remark about the opening gondola scene from Phantom of the Opera, joking that it wasn't Cunard's boat, but rather Andrew Lloyd Webber's mode of transportation.Cole Escola, playwright of Oh, Mary!, expressed gratitude to a rather unconventional recipient: "my amazing husband, who doesn’t exist". This humorous comment set the tone for a night filled with both laughter and heartfelt acknowledgments.Elaine Paige, a special award winner, shared the secret to her long-lasting career, attributing her success to her father's motto: "perseverance furthers". This insight into her personal life added a touching element to the evening.Rachel Zegler, winner of the best actress in a musical for her role in Evita, recalled her experience performing in the Palladium balcony, calling it "the honour of a lifetime". Her sentiment encapsulated the pride and gratitude felt by many of the winners.Rosamund Pike, best actress winner, reflected on the challenges of balancing life and art, acknowledging the support of her family and partner. Her words resonated with the audience, highlighting the importance of a strong support system.The ceremony also saw Jack Holden win the surprise best actor award, who, upon hearing his name, jokingly asked, "It was definitely me, was it?". This lighthearted moment brought humor to the event.Throughout the evening, winners shared their appreciation for their loved ones and mentors. James Hameed thanked his dad, who had come to London to chase his dreams, showcasing the impact of family on one's journey to success.

Rachel Zegler has hailed the accessibility of Evita's free balcony scene, which became a landmark moment for London sightseers during the show's run last summer. The scene, which featured Zegler performing 'Don't Cry for Me Argentina' from the balcony of the London Palladium to crowds gathered on the street below, was a groundbreaking moment in theatre. At the Olivier awards on Sunday night, Zegler delivered the song again – this time on the stage of the Royal Albert Hall – and took home the award for best actress in a musical. Host Nick Mohammed noted that Zegler had become 'a new landmark for London sightseers' during Evita's run, allowing people who hadn't bought a ticket to watch the performance live for free on a giant screen. Zegler described Evita's director, Jamie Lloyd, as a 'genius' for staging the scene in such a way, giving 'a piece of theatre, just in the street' to young people who may not be able to afford West End ticket prices. 'It's so beautiful that Jamie Lloyd made such an accessible moment of theatre for people to walk by and witness something really, really cool,' she said. The actor, whose musical films include West Side Story and Snow White, praised Londoners for making her feel welcome and described those who had waited outside to watch the balcony scene as being 'so giving with their energy and love'. Zegler also acknowledged the difficulty of replicating the balcony scene, but she and Andrew Lloyd Webber have spoken of their hope that Evita will transfer to Broadway. Evita picked up two awards from five nominations at the Olivier awards, with choreographer Fabian Aloise also recognised for his work. The show was beaten to the prize for best musical revival by Into the Woods at the Bridge theatre.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Booking.com, a leading accommodation reservation website, has suffered a significant data breach that has exposed customer information to unauthorized parties. The company, which lists over 30 million accommodation venues worldwide, detected suspicious activity involving unauthorized access to some guests' booking information.Upon discovering the breach, Booking.com took immediate action to contain the issue and updated the PIN numbers for affected reservations. The company has also informed affected customers about the breach. According to Booking.com, financial information was not accessed during the breach.The breach is the latest in a series of cybercrime attempts on Booking.com, which has recently struggled with a rising number of online scams on its platform. In 2018, the company reported a breach that exposed the booking data of over 4,000 people. Booking.com was fined €475,000 for reporting the breach 22 days late to the Dutch privacy regulator.The company, owned by Booking Holdings, a $137 billion US company, employs over 24,000 people worldwide. The breach highlights the growing concern of fake listings on booking websites and the need for increased cybersecurity measures in the industry.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

At the break of day in Keswick, the air still carries a chill despite it being April. From a drystone wall on St John’s Vale, I watched the sky race past Helvellyn, while bright daffodils bowed on a nearby farm as if shivering in the breeze. The surrounding trees stood still, and a shaft of sunlight ignited the bracken below the crags, turning it a vivid colour that starkly contrasted with the dead grass and dark scree. This scene illustrates a place where change has settled gently, with farms preserving their protective belts of trees that nestle comfortably against the fell’s edge.The low fields echoed with the call of curlews, and although some farmers elsewhere lament a lack of moisture, the land here was saturated; the river ran brown with flood‑water and the becks churned white. Many ewes were gathered for lambing, yet one independent ewe chose to give birth alone on a small green shelf in a ghyll above a stream. The newborn lamb was still damp and trembling when a farmhand arrived in his tractor, loading the pair onto a hay‑lined trailer to bring them back to the safety of the farm, fearing the lamb might tumble into the beck as its mother went to drink.